RNA Viruses and Antibody Response

doi:10.3390/books978-3-7258-0109-1

Download Url(s)

https://mdpi.com/books/pdfview/book/8702

Contributor(s)

Kam, Jason Yiu Wing (editor)

Language

English

Show full item record

Abstract

This Special Issue comprises 14 original studies and 2 reviews, and will serve as a platform to further the current knowledge of antibody responses against RNA virus infections.

URI

https://directory.doabooks.org/handle/20.500.12854/137536

Keywords

SARS-CoV-2; HIV/AIDS; SARS-CoV-2 vaccine; Omicron variant; neutralization titers; third dose vaccine; Chikungunya virus; immunoinformatics; B-cell epitopes; peptides; ELISA; COVID-19; RBD; immunogenicity; mutant; cohort study; antibody waning; seroreactivity; electrochemiluminescence assay; fixed-effect models; nursing home; epidemiology; seroprevalence; pre-vaccination; nucleocapsid phosphoprotein; monoclonal antibody; recombinant protein; cross-reactivity; epitopes; mapping antibody repertoires; original antigenic sin; immune imprinting; repeated influenza exposures; broadly neutralizing antibody; influenza A H3N2 virus; sotrovimab; nirmatrelvir/ritonavir; molnupiravir; remdesivir; human infection; repeated infection; HIV-1; RSV; neutralizing antibody; neutralization assay; epitope specificity; analysis of serum antibody specificity; antibody dynamics; vaccine; protection time; mathematical modeling; multiple myeloma; ritonavir-nirmatrelvir; belantamab mafodotin; T cell response; breakthrough infection; influenza; antibody; virus; convalescent plasma; meta-analysis; randomized controlled trials; mortality; intensive care unit; antibody response; RNA viruses; infection; vaccination; nucleocapsid protein; spike protein; n/a